P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

Background Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer. Methods We retrospectively reviewed and analyzed the clinical features and response to standard systemic therapy of 145 patients with documented tumor p53 mutational status (mutant-type [mtp53] vs. wild-type [wtp53]) referred to the Clinical Center for Targeted Therapy. Results Sixty-six (45.5%) patients had mtp53. Mutations in p53 occurred more frequently in older patients (p= 0.015) and in Caucasians (p=0.024). The incidence of liver metastases was 69.2% vs. 43%, p=0.002 in mtp53 and wtp53, respectively. PTEN loss by immunohistochemistry was found more frequently in mtp53-bearing tumors compared to wtp53 (33.3% vs. 10%, p=0.007). The best progression-free survival (PFS) on standard systemic therapy was significantly longer with bevacizumab-containing regimens as compared to non-bevacizumab containing regimen in patients with mtp53 (median 11.0 [95% CI 5.9-16.0], n=22 vs. 4.0 months [95% CI 3.6-5.7], n=35, p<0.0001) but not those with wtp53 (median 5.0 [95% CI 2.0-7.6] vs. 6.0 [95% CI 4.0-7.5] months, p=0.318. The median overall survival from diagnosis in patients with mtp53 and wtp53 was 7.4 [95% CI 6.3-9.8] vs. 11.8 [95% CI 2.9-21.5] years, respectively (p=0.365). Conclusion Patients with mtp53 tumors were older at diagnosis, had more incidence of liver metastasis, and more frequent PTEN loss. The best PFS on standard systemic therapy was significantly longer with bevacizumab-containing regimens in patients with mutant p53 tumors but not in those with wtp53.

[1]  K. Friedrich,et al.  Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature , 2012, BMC Cancer.

[2]  Thierry Soussi,et al.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors , 2012, Proceedings of the National Academy of Sciences.

[3]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[4]  J. Vinagre,et al.  Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas , 2010, British Journal of Ophthalmology.

[5]  S. Chandarlapaty,et al.  Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[6]  Zhiwei Wang,et al.  MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. , 2010, European journal of cancer.

[7]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[8]  Tsuyoshi Arai,et al.  Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.

[9]  H. Koeppen,et al.  Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.

[10]  S. Sommer,et al.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Ogino,et al.  PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. , 2008, Neoplasia.

[12]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[13]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[14]  W. Cai,et al.  An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. , 2007, The Journal of clinical investigation.

[15]  Michael R. Green,et al.  Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome , 2007, Journal of Molecular Medicine.

[16]  M. Ihnat,et al.  Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. , 2007, Cancer letters.

[17]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[19]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[20]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Jubb,et al.  Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.

[22]  A. Levine,et al.  The coordinate regulation of the p53 and mTOR pathways in cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  U. Moll,et al.  The MDM2-p53 interaction. , 2003, Molecular cancer research : MCR.

[24]  E. Keystone,et al.  Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. , 2003, Experimental hematology.

[25]  S. Lai,et al.  Mutations in the p53 Tumor Suppressor Gene and Early Onset Breast Cancer , 2002, Cancer biology & therapy.

[26]  T. Mak,et al.  Regulation of PTEN transcription by p53. , 2001, Molecular cell.

[27]  C. Meijer,et al.  Absence of tpr–met and expression of c‐met in human gastric mucosa and carcinoma , 2001, The Journal of pathology.

[28]  T. Lindahl,et al.  The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. , 2001, Cancer research.

[29]  C. Bonaïti‐pellié,et al.  Sensitivity and predictive value of criteria for p53germline mutation screening , 2001, Journal of medical genetics.

[30]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Kosma,et al.  p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women , 2000, Molecular pathology : MP.

[32]  R. Henriksson,et al.  p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma , 2000, International journal of cancer.

[33]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[34]  M. Kelly,et al.  Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  P. Chumakov,et al.  Chromosome changes caused by alterations of p53 expression. , 1996, Mutation research.

[36]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[37]  P. Scardino,et al.  Association of p53 mutations with metastatic prostate cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  V. Chen,et al.  Racial disparity in the association of p53 gene alterations with breast cancer survival. , 1995, Cancer research.

[39]  A. Craft,et al.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. , 1994, Cancer research.

[40]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[41]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[42]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[43]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[44]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[45]  LI-YaLi,et al.  Mutations of p53 gene exons 4-8 in human esophageal cancer , 2005 .

[46]  K. Hörmann,et al.  Vascular Endothelial Growth Factor Expression Correlates with p53 Mutation and Angiogenesis in Squamous Cell Carcinoma of the Head and Neck , 2000, Acta oto-laryngologica.